Therefore, AC5 appears to have pharmacological potential, because suppressing the activity of AC5, and not the entire β-AR signaling pathway, may be preferable to current β-AR blockade therapy for the treatment of HF and arrhythmia. The gene discussed is ADCY5; the disease is hydrops fetalis.